Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Post-Traumatic Stress Disorders
Interventions: individualized Transcranial Magnetic Stimulation; Device
Lead sponsor: 72nd Medical Group, Tinker Air Force Base; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712 + ADT, Placebo + ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 37
States / cities: Arcadia, California • Beverly Hills, California • Fresno, California + 34 more

Conditions: Dyslipidaemias, Dyslipidemias
Interventions: 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more

Conditions: Knee Osteoarthritis
Interventions: DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Inflammation
Interventions: n3-PUFA, Placebo, Biopsy, Body Composition Scan; Drug · Procedure · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Social Anxiety Disorder
Interventions: D-Cycloserine, Placebo, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: Jasper A. Smits; Other
Eligibility: 18 Years to 70 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • Austin, Texas

Conditions: Stress
Interventions: Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI; Drug · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Rotator Cuff Injuries
Interventions: Triangular Forearm Support, Placebo; Behavioral
Lead sponsor: Manhattan Physical Medicine and Rehabilitation, LLP; Other
Eligibility: 21 Years and older
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcoholism
Interventions: Thiopental, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 30 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Osteoarthritis, Knee
Interventions: mHACMb, placebo; Drug · Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ligament Injury, Ligament; Laxity, Tendon Rupture, Tendon Injuries
Interventions: methylsulfonylmethane, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Davis, California

Conditions: Diabetes Mellitus
Interventions: PATH electronic decision support tool; Other
Lead sponsor: St Elizabeth Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Covington, Kentucky

Conditions: Alcoholism
Interventions: Computerized Alcohol Misuse Intervention, Attention Control (AC); Other
Lead sponsor: Research Circle Associates, LLC; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thrombocytopenia Associated With Liver Disease
Interventions: avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more

Conditions: Anxiety
Interventions: 2 mg Melatonin, 10mg Melatonin, Placebo; Drug · Other
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: San Diego, California • Portsmouth, Virginia

Conditions: Agitation, Dementia
Interventions: T2:C100, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 6 more

Conditions: Abortion, Blood Loss
Interventions: Misoprostol, Folic acid; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ureter Injury
Interventions: Saline Injection 0.9%, Indigotindisulfonate sodium 0.8%; Other · Drug
Lead sponsor: Prove pharm; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Albany, New York

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Diego, California • New York, New York

Conditions: Preeclampsia Postpartum
Interventions: Aspirin 81 mg, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Auditory Hallucination, Schizophrenia
Interventions: Transcranial direct-current stimulation (tDCS), Placebo; Device
Lead sponsor: Manhattan Psychiatric Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: PF-07321332, Ritonavir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 73
States / cities: Pelham, Alabama • Mesa, Arizona • Tucson, Arizona + 46 more

Conditions: Atrial Fibrillation
Interventions: Melatonin, Placebo (for Melatonin); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 280
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more

Search by objective public record fields.

To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

Enhancing Adaptations to Exercise

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

Automatic Multimodal Assessment of Occurrence and Intensity of Pain for Research and Clinical Use

GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence

Safety & Efficacy FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to OA of the Knee

Methylsulfonylmethane on Knee Laxity

Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes

Computerized Alcohol Misuse Intervention System for Health Care

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Premedication With Melatonin in Lumbar Medial Branch Block Procedure

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion

Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment

Maintenance rTMS for Depression (Maitr-De)

Aspirin and Preeclampsia

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma